GgoogleDE first seen 1 d ago, last 1 d ago, peak #3

Merck KGaA to acquire Silence Therapeutics in $1.3 billion deal

Original: silence therapeutics

Merck KGaA has agreed to buy Silence Therapeutics in a deal valued at roughly $1.3 billion, moving just weeks after the company's siRNA drug showed positive phase 2 results in a blood cancer. The acquisition gives the German pharma group Silence's RNA interference technology and pipeline. Analysts see it as a bet on next-generation genetic medicine.

Why now: The buyout follows the drug's successful phase 2 blood cancer results, making it fresh M&A news in biotech.

Merck KGaASilence Therapeutics

Open on google →

Rank over time, top of the chart is #1. 2 snapshots from 1 d ago to 1 d ago.

Evidence

• Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win · Fierce Biotech

API: https://socialmediatrends-api.osmike.com/v1/trends/2870735